Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
Open Access
- 7 June 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (9), 1245-1246
- https://doi.org/10.1136/annrheumdis-2021-220049
Abstract
No abstract availableFunding Information
- Pfizer (61448843)
This publication has 7 references indexed in Scilit:
- Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need FulfilledThe New England Journal of Medicine, 2021
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19The New England Journal of Medicine, 2021
- JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortalityScience Advances, 2021
- A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinibExpert Opinion on Drug Safety, 2020
- Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patientsEMBO Molecular Medicine, 2020
- COVID-19: combining antiviral and anti-inflammatory treatmentsThe Lancet Infectious Diseases, 2020
- Baricitinib as potential treatment for 2019-nCoV acute respiratory diseaseThe Lancet, 2020